Réf :HematoStat.net ; 2 (4) : V56 EORTC Quality of Life Group. International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic […]

Réf :HematoStat.net ; 2 (4) : V55 Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy. Voso MT, Pandzic T, […]

Réf :HematoStat.net ; 2 (4) : V54 Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio […]

Réf :HematoStat.net ; 2 (4) : V53 Management of cardiovascular complications of bruton tyrosine kinase inhibitors. Tang CPS, Lip GYH, McCormack T, Lyon AR, Hillmen P, Iyengar S, Martinez-Calle N, […]

Réf :HematoStat.net ; 2 (4) : V52 Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. Rigolin GM, Del Giudice I, […]

Réf :HematoStat.net ; 2 (4) : V51 Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, […]

Réf :HematoStat.net ; 2 (4) : V50 The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf […]